Try our beta test site
124 studies found for:    Florida [LOCATION] | Open Studies | Lymphoma OR CLL
Show Display Options
Rank Status Study
81 Recruiting HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Conditions: Myelodysplastic Syndrome (MDS);   Chronic Lymphocytic Leukemia (CLL);   Chemotherapy-sensitive Lymphoma;   Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma;   Acute Myelogenous Leukemia (AML);   Acute Biphenotypic Leukemia (ABL);   Acute Undifferentiated Leukemia (AUL)
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5;   Radiation: Total Body Irradiation (TBI) 200cGy on Day -1;   Procedure: Infusion of non-T-cell depleted bone marrow on Day 0;   Drug: Busulfan;   Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1;   Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4;   Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1;   Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4;   Drug: Sirolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Drug: Pre-HCT Mesna on Days -6 and -5;   Drug: Pre-HCT Mesna on Days -2 and -1;   Drug: Pre-HCT Mesna on Days -5 and -4;   Drug: Post-HCT Mesna
82 Recruiting DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Conditions: B-cell Non-Hodgkin Lymphoma;   Aggressive
Interventions: Other: collected at pre-treatment tumor biopsy;   Other: Peripheral blood tests;   Device: PET/CT
83 Recruiting A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Conditions: Lymphoblastic Leukemia, Acute, Childhood;   Lymphoblastic Lymphoma;   Peripheral T-cell Lymphoma
Interventions: Drug: Temsirolimus;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Hydrocortisone;   Drug: Cytarabine
84 Recruiting A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies
Conditions: Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: REGN1979 multiple dose levels
85 Not yet recruiting A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response
Condition: Hodgkin Disease
Interventions: Biological: Nivolumab;   Biological: brentuximab vedotin;   Biological: bendamustine
86 Recruiting Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
Conditions: Advanced Solid Tumors;   Advanced B-cell NHL
Interventions: Biological: Urelumab;   Biological: Nivolumab
87 Recruiting Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Conditions: Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
Intervention: Drug: Entrectinib
88 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
Conditions: AIDS-Related Hodgkin Lymphoma;   CD30-Positive Neoplastic Cells Present;   Classical Hodgkin Lymphoma;   HIV Infection;   Stage II Hodgkin Lymphoma;   Stage IIA Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage III Hodgkin Lymphoma;   Stage IIIA Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IV Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vinblastine
89 Recruiting Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Conditions: Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult T-Cell Leukemia/Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-Cell Leukemia/Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult T-Cell Leukemia/Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult T-Cell Leukemia/Lymphoma;   Stage IV Childhood Hodgkin Lymphoma
Interventions: Other: Assessment of Therapy Complications;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
90 Recruiting Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Condition: B Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
91 Recruiting Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   CD19 Positive;   Mediastinal Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions: Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
92 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Platelets;   Histiocytic Disorders;   Acute Myelogenous Leukemia (AML or ANLL);   Acute Lymphoblastic Leukemia (ALL);   Other Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;   Other Leukemia;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple Myeloma/ Plasma Cell Disorder (PCD);   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Disorders of the Immune System;   Automimmune Diseases;   Severe Aplastic Anemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
93 Recruiting An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, With or Without Pomalidomide and Dexamethasone, in Patients With Multiple Myeloma
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Lirilumab;   Biological: Daratumumab;   Drug: Pomalidomide;   Drug: Dexamethasone
94 Recruiting Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Leukemia Acute Myeloid;   Lymphoma, Non-Hodgkin;   Myelodysplastic Syndrome;   Immunologic Deficiency Syndromes
Interventions: Biological: BPX-501 T cells and AP1903;   Drug: AP1903
95 Recruiting TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Condition: Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Sapanisertib
96 Recruiting Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Conditions: Acute Undifferentiated Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies;   Childhood Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hairy Cell Leukemia;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Neoplasm of Uncertain Malignant Potential;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
97 Recruiting Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Adult T Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
98 Recruiting Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
Condition: Childhood Acute Lymphoblastic Leukemia in Remission
Interventions: Behavioral: behavioral intervention;   Drug: mercaptopurine;   Procedure: standard follow-up care;   Behavioral: compliance monitoring;   Other: questionnaire administration;   Other: laboratory biomarker analysis
99 Recruiting A Study of LY3039478 in Participants With Advanced Cancer
Conditions: Neoplasms;   Neoplasm Metastasis;   Lymphoma
Intervention: Drug: LY3039478
100 Recruiting A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Condition: B-cell Acute Lymphoblastic Leukemia
Interventions: Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate

First Page    Show previous page of results Previous Page (61-80) Studies Shown (81-100) Next Page (101-120) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.